Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

Inflammatory Bowel Diseases

Volumn 18, Issue 1, 2012, Pages 174-179

  Clarke, Kofi ^a   Regueiro, Miguel ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

6 mercaptopurine; anti tumor necrosis factor agents; azathioprine; Crohn's disease; stopping treatment; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; HEMOGLOBIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

CLINICAL EVALUATION; CROHN DISEASE; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS;

BIOLOGICAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; RECURRENCE; REMISSION INDUCTION;

EID: 83555174451     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21792     Document Type: Review

References (19)

1. Colombel J-F, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. Gastroenterology. 2010; 138 (suppl 1): S158.
2. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double blind withdrawal of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978; 2: 955-957. (Pubitemid 9061740)
3. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347: 215-219. (Pubitemid 26035245)
4. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol. 1999; 94: 3254-3257.
5. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128: 1812-1818. (Pubitemid 40824692)
6. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009; 7: 80-85.
7. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992; 305: 20-22.
8. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50: 485-489. (Pubitemid 34638866)
9. Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol. 2004; 99: 462-465. (Pubitemid 38524124)
10. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol. 2009; 104: 2760-2767.
11. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors. A prospective ongoing cohort study. Gastroenterology. 2009; 136: A-146.
12. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492-500.
13. Waugh AW, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Phamacol Ther. 2010; 32: 1129-1134.
14. Regueiro M, KKip K, Schraut W, et al. 4.5 yr follow-up of patients enrolled in the randomized controlled trial (RCT) of infliximab (INF) for prevention of postoperative Crohn's disease. Gastroenterology 2010: A542.
15. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010; 105: 1142-1149.
16. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005; 52: 27-35. (Pubitemid 40129229)
17. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52: 3381-3390. (Pubitemid 41612204)
18. Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008; 18: 460-464.
19. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010; 69: 1286-1291.